Miramar Eye Specialists — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$29,880	49
2023	Research	$4,200	2
2022	Research	$3,952	2
2021	Research	$42,929	16
2020	Research	$93,344	16
2019	Research	$44,753	12

Breakdown

Who paid Research payments · program years 2019–2024

Novartis Pharmaceuticals Corporation $110,473 6 payments
Glaukos Corporation $74,505 40 payments
Alcon Research LLC $34,080 51 payments

Studies the money was for Research payments · program years 2019–2024

A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $80,742 2 payments
Next Generation Cataract Surgery Study $34,080 51 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $23,855 11 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $23,811 14 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $22,970 14 payments
A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $18,037 2 payments
A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $11,694 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.